EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study

Carolina Sciortino, Federico Nichetti, Francesca Bergamo, Federica Palermo, Stefano Tamberi, Caterina Vivaldi, Elena Ongaro, Giuseppina Arcangeli, Silvia Marchesi, Elisa Giommoni, Chiara Alessandra Cella, Chiara Pircher und 28 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.11.007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Carolina Sciortino und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Paclitaxel, Deoxycytidine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Rising Tide Foundation for Clinical Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Advanced pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal cancers, with >95 % of patients dying from the disease. Chemotherapy is the standard of care in advanced stages, with FOLFIRINOX and Gemcitabine-Nab-Paclitaxel (Gem-NabP) as the main first-line regimens. Both show moderate efficacy and significant toxicity. Except for the PASS-01 trial, no direct comparison exists, though observational studies suggest that specific subgroups may benefit differently. Given the modest outcomes and rapid clinical decline, most patients are ineligible for second-line therapy after progression. The PANThEON study evaluates whether switching from modified FOLFIRINOX (mFOLFIRINOX) to Gem-NabP after three months of induction with mFOLFIRINOX improves outcomes for PDAC. METHODS: PANThEON is a no-profit, phase III, randomized, open-label, multicenter trial. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), time to treatment failure (TTF), overall response rate (ORR), and quality of life (QoL). Exploratory analyses will assess tumor profiling, circulating tumor DNA (ctDNA), and radiomics to identify predictive markers. A total of 220 patients will be randomized 1:1 to Gem-NabP (arm B) or continued mFOLFIRINOX (arm A). DISCUSSION: The PANThEON trial addresses two challenges: improving efficacy while reducing toxicity. Switching to Gem-NabP may enhance tolerability without compromising benefit, prolonging survival and refining PDAC treatment strategies. TRIAL REGISTRATION: PANThEON is registered at ClinicalTrials.gov (NCT06897644) and EuCT (2024-515214-41-00).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsPaclitaxelDeoxycytidineAlbuminsCarcinoma, Pancreatic DuctalHumansIrinotecanLeucovorinFluorouracilGemcitabineOxaliplatinRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicMulticenter Studies as TopicMaleFemaleMiddle AgedAgedQuality of Life

Stichwörter der Autor:innen

ChemotherapyClinical trialGemcitabine plus NabpaclitaxelPancreatic cancerSwitch maintenancemFOLFIRINOX

Substanzen

Paclitaxel130-nm albumin-bound paclitaxelIrinotecanLeucovorinFluorouracilGemcitabineDeoxycytidinefolfirinoxAlbuminsOxaliplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy.
  • Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Oncology Unit, Ospedale Santa Maria elle Croci Ravenna AUSL Romagna, Italy; DIMEC University of Bologna, Italy.
  • Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano (PN), Italy.
  • Department of Medical Oncology, ASST Spedali Civili, Brescia, Italy.

Förderung

  • Rising Tide Foundation for Clinical Cancer Research

Zitieren

APA

Sciortino, C., Nichetti, F., Bergamo, F., Palermo, F., Tamberi, S., Vivaldi, C., Ongaro, E., Arcangeli, G., Marchesi, S., Giommoni, E., Cella, C. A., Pircher, C., Chiaramonte, A., Bencardino, K., Sottotetti, E., Martinetti, A., Rapposelli, I. G., Corallo, S., Di Donato, S., …, & Niger, M. (2025). A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.11.007

Vancouver

Sciortino C, Nichetti F, Bergamo F, Palermo F, Tamberi S, Vivaldi C, et al. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.11.007

BibTeX
@article{Sciortino2025,
  author = {Sciortino, Carolina and Nichetti, Federico and Bergamo, Francesca and Palermo, Federica and Tamberi, Stefano and Vivaldi, Caterina and Ongaro, Elena and Arcangeli, Giuseppina and Marchesi, Silvia and Giommoni, Elisa and Cella, Chiara Alessandra and Pircher, Chiara and Chiaramonte, Anna and Bencardino, Katia and Sottotetti, Elisa and Martinetti, Antonia and Rapposelli, Ilario Giovanni and Corallo, Salvatore and Di Donato, Samantha and Murialdo, Roberto and Delliponti, Laura and Salvatore, Lisa and Bozzarelli, Silvia and Dell'Aquila, Emanuela and Miceli, Rosalba and Carnaghi, Carlo and Tomasello, Gianluca and Rivizzigno, Piero and Bonomi, Maria and Mannavola, Francesco and Forti, Laura and Garajovà, Ingrid and Attademo, Laura and Galassi, Barbara and Chiari, Rita and Leone, Francesco and Garattini, Silvio Ken and Tamburini, Emiliano and Pietrantonio, Filippo and Niger, Monica},
  title = {A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.11.007}
}
Kostenlos starten →